ID   PLAK_HUMAN              Reviewed;         745 AA.
AC   P14923; Q15093; Q15151; Q7L3S5; Q86W21; Q9BWC4; Q9HCX9;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 3.
DT   07-APR-2021, entry version 214.
DE   RecName: Full=Junction plakoglobin;
DE   AltName: Full=Catenin gamma;
DE   AltName: Full=Desmoplakin III;
DE   AltName: Full=Desmoplakin-3;
GN   Name=JUP; Synonyms=CTNNG, DP3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2726765; DOI=10.1073/pnas.86.11.4027;
RA   Franke W.W., Goldschmidt M.D., Zimbelmann R., Mueller H.M., Schiller D.L.,
RA   Cowin P.;
RT   "Molecular cloning and amino acid sequence of human plakoglobin, the common
RT   junctional plaque protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:4027-4031(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Zimbelmann R.;
RL   Submitted (DEC-1995) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11016852; DOI=10.1034/j.1600-0625.2000.009005323.x;
RA   Whittock N.V., Eady R.A.J., McGrath J.A.;
RT   "Genomic organization and amplification of the human plakoglobin gene
RT   (JUP).";
RL   Exp. Dermatol. 9:323-326(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-697.
RC   TISSUE=Epidermal carcinoma;
RA   Liang X.-J., Gottesman M.M.;
RT   "Homo sapiens gamma-catenin mRNA from human KB epidermoid adenocarcinoma
RT   cells.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-697.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-697.
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 1-12; 116-142; 150-172; 177-203; 217-233; 273-279;
RP   304-320; 327-333; 368-394; 427-460; 466-533; 583-602; 638-661 AND 664-674,
RP   ACETYLATION AT MET-1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma, and Lung carcinoma;
RA   Bienvenut W.V., Vousden K.H., Lukashchuk N., Calvo F., Kolch W.;
RL   Submitted (MAR-2008) to UniProtKB.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 634-745, VARIANT LEU-697, AND
RP   INVOLVEMENT IN NAXOS DISEASE.
RC   TISSUE=Leukocyte;
RX   PubMed=10902626; DOI=10.1016/s0140-6736(00)02379-5;
RA   McKoy G., Protonotarios N., Crosby A., Tsatsopoulou A., Anastasakis A.,
RA   Coonar A., Norman M., Baboonian C., Jeffery S., McKenna W.J.;
RT   "Identification of a deletion in plakoglobin in arrhythmogenic right
RT   ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair
RT   (Naxos disease).";
RL   Lancet 355:2119-2124(2000).
RN   [10]
RP   IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX.
RX   PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9;
RA   Butz S., Kemler R.;
RT   "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell
RT   adhesion.";
RL   FEBS Lett. 355:195-200(1994).
RN   [11]
RP   DOMAIN, AND INTERACTION WITH CTNNA1; DSC1 AND DSG1.
RX   PubMed=8631907; DOI=10.1074/jbc.271.18.10904;
RA   Witcher L.L., Collins R., Puttagunta S., Mechanic S.E., Munson M.,
RA   Gumbiner B., Cowin P.;
RT   "Desmosomal cadherin binding domains of plakoglobin.";
RL   J. Biol. Chem. 271:10904-10909(1996).
RN   [12]
RP   INTERACTION WITH MUC1.
RX   PubMed=9139698; DOI=10.1074/jbc.272.19.12492;
RA   Yamamoto M., Bharti A., Li Y., Kufe D.;
RT   "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-
RT   catenin in cell adhesion.";
RL   J. Biol. Chem. 272:12492-12494(1997).
RN   [13]
RP   INTERACTION WITH CTNNA1.
RX   PubMed=9152027;
RA   Nieset J.E., Redfield A.R., Jin F., Knudsen K.A., Johnson K.R.,
RA   Wheelock M.J.;
RT   "Characterization of the interactions of alpha-catenin with alpha-actinin
RT   and beta-catenin/plakoglobin.";
RL   J. Cell Sci. 110:1013-1022(1997).
RN   [14]
RP   INTERACTION WITH PTPRJ.
RX   PubMed=12370829; DOI=10.1038/sj.onc.1205858;
RA   Holsinger L.J., Ward K., Duffield B., Zachwieja J., Jallal B.;
RT   "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts
RT   with p120(ctn).";
RL   Oncogene 21:7067-7076(2002).
RN   [15]
RP   GLYCOSYLATION AT THR-14, AND MUTAGENESIS OF THR-14; THR-19; THR-21; SER-24;
RP   SER-28 AND THR-32.
RX   PubMed=12847106; DOI=10.1074/jbc.m301346200;
RA   Hatsell S., Medina L., Merola J., Haltiwanger R., Cowin P.;
RT   "Plakoglobin is O-glycosylated close to the N-terminal destruction box.";
RL   J. Biol. Chem. 278:37745-37752(2003).
RN   [16]
RP   PHOSPHORYLATION BY FER.
RX   PubMed=14517306; DOI=10.1128/mcb.23.20.7391-7402.2003;
RA   Miravet S., Piedra J., Castano J., Raurell I., Franci C., Dunach M.,
RA   Garcia de Herreros A.;
RT   "Tyrosine phosphorylation of plakoglobin causes contrary effects on its
RT   association with desmosomes and adherens junction components and modulates
RT   beta-catenin-mediated transcription.";
RL   Mol. Cell. Biol. 23:7391-7402(2003).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-182 AND SER-665, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-665, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   INTERACTION WITH DSC2.
RX   PubMed=21062920; DOI=10.1093/cvr/cvq353;
RA   Gehmlich K., Syrris P., Peskett E., Evans A., Ehler E., Asimaki A.,
RA   Anastasakis A., Tsatsopoulou A., Vouliotis A.I., Stefanadis C.,
RA   Saffitz J.E., Protonotarios N., McKenna W.J.;
RT   "Mechanistic insights into arrhythmogenic right ventricular cardiomyopathy
RT   caused by desmocollin-2 mutations.";
RL   Cardiovasc. Res. 90:77-87(2011).
RN   [21]
RP   INTERACTION WITH PKP2, AND SUBCELLULAR LOCATION.
RX   PubMed=22781308; DOI=10.1161/circgenetics.111.961854;
RA   Kirchner F., Schuetz A., Boldt L.H., Martens K., Dittmar G., Haverkamp W.,
RA   Thierfelder L., Heinemann U., Gerull B.;
RT   "Molecular insights into arrhythmogenic right ventricular cardiomyopathy
RT   caused by plakophilin-2 missense mutations.";
RL   Circ. Cardiovasc. Genet. 5:400-411(2012).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99; SER-125; SER-182 AND
RP   SER-730, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 124-676 IN COMPLEX WITH
RP   PHOSPHORYLATED MOUSE E-CADHERIN, DOMAIN ARM REPEATS, AND INTERACTION WITH
RP   DSC1 AND DSG1.
RX   PubMed=19759396; DOI=10.1074/jbc.m109.047928;
RA   Choi H.J., Gross J.C., Pokutta S., Weis W.I.;
RT   "Interactions of plakoglobin and beta-catenin with desmosomal cadherins:
RT   basis of selective exclusion of alpha- and beta-catenin from desmosomes.";
RL   J. Biol. Chem. 284:31776-31788(2009).
RN   [25]
RP   VARIANT ARVD12 SER-39 INS, AND CHARACTERIZATION OF VARIANT ARVD12 SER-39
RP   INS.
RX   PubMed=17924338; DOI=10.1086/521633;
RA   Asimaki A., Syrris P., Wichter T., Matthias P., Saffitz J.E., McKenna W.J.;
RT   "A novel dominant mutation in plakoglobin causes arrhythmogenic right
RT   ventricular cardiomyopathy.";
RL   Am. J. Hum. Genet. 81:964-973(2007).
RN   [26]
RP   VARIANT ARVD12 ILE-19, AND VARIANTS HIS-142; ILE-648 AND LEU-697.
RX   PubMed=20031617; DOI=10.1161/circgenetics.109.858217;
RA   den Haan A.D., Tan B.Y., Zikusoka M.N., Llado L.I., Jain R., Daly A.,
RA   Tichnell C., James C., Amat-Alarcon N., Abraham T., Russell S.D.,
RA   Bluemke D.A., Calkins H., Dalal D., Judge D.P.;
RT   "Comprehensive desmosome mutation analysis in North Americans with
RT   arrhythmogenic right ventricular dysplasia/cardiomyopathy.";
RL   Circ. Cardiovasc. Genet. 2:428-435(2009).
RN   [27]
RP   VARIANTS HIS-142 AND LEU-697.
RX   PubMed=19863551; DOI=10.1111/j.1399-0004.2009.01282.x;
RA   Barahona-Dussault C., Benito B., Campuzano O., Iglesias A., Leung T.L.,
RA   Robb L., Talajic M., Brugada R.;
RT   "Role of genetic testing in arrhythmogenic right ventricular
RT   cardiomyopathy/dysplasia.";
RL   Clin. Genet. 77:37-48(2010).
CC   -!- FUNCTION: Common junctional plaque protein. The membrane-associated
CC       plaques are architectural elements in an important strategic position
CC       to influence the arrangement and function of both the cytoskeleton and
CC       the cells within the tissue. The presence of plakoglobin in both the
CC       desmosomes and in the intermediate junctions suggests that it plays a
CC       central role in the structure and function of submembranous plaques.
CC       Acts as a substrate for VE-PTP and is required by it to stimulate VE-
CC       cadherin function in endothelial cells. Can replace beta-catenin in E-
CC       cadherin/catenin adhesion complexes which are proposed to couple
CC       cadherins to the actin cytoskeleton (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer. Component of an E-cadherin/catenin adhesion complex
CC       composed of at least E-cadherin/CDH1 and gamma-catenin/JUP, and
CC       possibly alpha-catenin/CTNNA1; the complex is located to adherens
CC       junctions. The stable association of CTNNA1 is controversial as CTNNA1
CC       was shown not to bind to F-actin when assembled in the complex.
CC       Interacts with MUC1. Interacts with CAV1 (By similarity). Interacts
CC       with PTPRJ. Interacts with DSG1. Interacts with DSC1 and DSC2.
CC       Interacts with PKP2. {ECO:0000250, ECO:0000269|PubMed:12370829,
CC       ECO:0000269|PubMed:19759396, ECO:0000269|PubMed:21062920,
CC       ECO:0000269|PubMed:22781308, ECO:0000269|PubMed:7982500,
CC       ECO:0000269|PubMed:8631907, ECO:0000269|PubMed:9139698,
CC       ECO:0000269|PubMed:9152027}.
CC   -!- INTERACTION:
CC       P14923; P25054: APC; NbExp=3; IntAct=EBI-702484, EBI-727707;
CC       P14923; A0A0S2Z4M1: AXIN1; NbExp=3; IntAct=EBI-702484, EBI-16429430;
CC       P14923; O15169: AXIN1; NbExp=4; IntAct=EBI-702484, EBI-710484;
CC       P14923; P19022: CDH2; NbExp=2; IntAct=EBI-702484, EBI-2256711;
CC       P14923; Q9UI47-2: CTNNA3; NbExp=3; IntAct=EBI-702484, EBI-11962928;
CC       P14923; Q9NSA3: CTNNBIP1; NbExp=4; IntAct=EBI-702484, EBI-747082;
CC       P14923; P26196: DDX6; NbExp=3; IntAct=EBI-702484, EBI-351257;
CC       P14923; Q02413: DSG1; NbExp=2; IntAct=EBI-702484, EBI-1045757;
CC       P14923; Q14192: FHL2; NbExp=7; IntAct=EBI-702484, EBI-701903;
CC       P14923; P23327: HRC; NbExp=2; IntAct=EBI-702484, EBI-9639760;
CC       P14923; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-702484, EBI-741158;
CC       P14923; P16284: PECAM1; NbExp=7; IntAct=EBI-702484, EBI-716404;
CC       P14923; P0CG20: PRR35; NbExp=3; IntAct=EBI-702484, EBI-11986293;
CC       P14923; Q9UHP6: RSPH14; NbExp=3; IntAct=EBI-702484, EBI-748350;
CC       P14923; Q9NQB0-10: TCF7L2; NbExp=3; IntAct=EBI-702484, EBI-11746252;
CC   -!- SUBCELLULAR LOCATION: Cell junction, adherens junction
CC       {ECO:0000269|PubMed:22781308}. Cell junction, desmosome
CC       {ECO:0000269|PubMed:22781308}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:22781308}. Membrane {ECO:0000269|PubMed:22781308};
CC       Peripheral membrane protein {ECO:0000269|PubMed:22781308}.
CC       Note=Cytoplasmic in a soluble and membrane-associated form.
CC   -!- DOMAIN: The entire ARM repeats region mediates binding to CDH1/E-
CC       cadherin. The N-terminus and first three ARM repeats are sufficient for
CC       binding to DSG1. The N-terminus and first ARM repeat are sufficient for
CC       association with CTNNA1. DSC1 association requires both ends of the ARM
CC       repeat region. {ECO:0000269|PubMed:19759396,
CC       ECO:0000269|PubMed:8631907}.
CC   -!- PTM: May be phosphorylated by FER. {ECO:0000269|PubMed:14517306}.
CC   -!- DISEASE: Naxos disease (NXD) [MIM:601214]: An autosomal recessive
CC       disorder characterized by the association of diffuse non-epidermolytic
CC       palmoplantar keratoderma with woolly hair and cardiac abnormalities
CC       such as dilated cardiomyopathy and arrhythmogenic right ventricular
CC       dysplasia. {ECO:0000269|PubMed:10902626}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Arrhythmogenic right ventricular dysplasia, familial, 12
CC       (ARVD12) [MIM:611528]: A congenital heart disease characterized by
CC       infiltration of adipose and fibrous tissue into the right ventricle and
CC       loss of myocardial cells, resulting in ventricular and supraventricular
CC       arrhythmias. {ECO:0000269|PubMed:17924338,
CC       ECO:0000269|PubMed:20031617}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the beta-catenin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH00441.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23410; AAA64895.1; -; mRNA.
DR   EMBL; Z68228; CAA92522.1; -; mRNA.
DR   EMBL; AF306723; AAG16727.1; -; Genomic_DNA.
DR   EMBL; AF233882; AAG16727.1; JOINED; Genomic_DNA.
DR   EMBL; AY243535; AAO85780.1; -; mRNA.
DR   EMBL; AC109319; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471152; EAW60762.1; -; Genomic_DNA.
DR   EMBL; BC000441; AAH00441.2; ALT_INIT; mRNA.
DR   EMBL; BC011865; AAH11865.1; -; mRNA.
DR   EMBL; AJ249711; CAC04246.1; -; Genomic_DNA.
DR   CCDS; CCDS11407.1; -.
DR   PIR; A32905; A32905.
DR   RefSeq; NP_002221.1; NM_002230.2.
DR   RefSeq; NP_068831.1; NM_021991.2.
DR   RefSeq; XP_006721936.1; XM_006721873.2.
DR   RefSeq; XP_006721937.1; XM_006721874.2.
DR   RefSeq; XP_006721938.1; XM_006721875.1.
DR   RefSeq; XP_006721941.1; XM_006721878.1.
DR   RefSeq; XP_011523055.1; XM_011524753.2.
DR   RefSeq; XP_011523057.1; XM_011524755.1.
DR   RefSeq; XP_011523058.1; XM_011524756.1.
DR   RefSeq; XP_011523059.1; XM_011524757.2.
DR   RefSeq; XP_011523060.1; XM_011524758.1.
DR   RefSeq; XP_016880079.1; XM_017024590.1.
DR   PDB; 3IFQ; X-ray; 2.80 A; A/B=124-676.
DR   PDBsum; 3IFQ; -.
DR   SMR; P14923; -.
DR   BioGRID; 109931; 274.
DR   CORUM; P14923; -.
DR   DIP; DIP-36235N; -.
DR   IntAct; P14923; 121.
DR   MINT; P14923; -.
DR   STRING; 9606.ENSP00000377508; -.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   GlyConnect; 1950; 10 N-Linked glycans (4 sites).
DR   GlyGen; P14923; 5 sites.
DR   iPTMnet; P14923; -.
DR   MetOSite; P14923; -.
DR   PhosphoSitePlus; P14923; -.
DR   SwissPalm; P14923; -.
DR   BioMuta; JUP; -.
DR   DMDM; 205371866; -.
DR   EPD; P14923; -.
DR   jPOST; P14923; -.
DR   MassIVE; P14923; -.
DR   MaxQB; P14923; -.
DR   PaxDb; P14923; -.
DR   PeptideAtlas; P14923; -.
DR   PRIDE; P14923; -.
DR   ProteomicsDB; 53098; -.
DR   Antibodypedia; 80391; 1254 antibodies.
DR   DNASU; 3728; -.
DR   Ensembl; ENST00000310706; ENSP00000311113; ENSG00000173801.
DR   Ensembl; ENST00000393930; ENSP00000377507; ENSG00000173801.
DR   Ensembl; ENST00000393931; ENSP00000377508; ENSG00000173801.
DR   GeneID; 3728; -.
DR   KEGG; hsa:3728; -.
DR   UCSC; uc002hxq.3; human.
DR   CTD; 3728; -.
DR   DisGeNET; 3728; -.
DR   GeneCards; JUP; -.
DR   GeneReviews; JUP; -.
DR   HGNC; HGNC:6207; JUP.
DR   HPA; ENSG00000173801; Tissue enhanced (esophagus, skin, tongue).
DR   MalaCards; JUP; -.
DR   MIM; 173325; gene.
DR   MIM; 601214; phenotype.
DR   MIM; 611528; phenotype.
DR   neXtProt; NX_P14923; -.
DR   OpenTargets; ENSG00000173801; -.
DR   Orphanet; 293899; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form.
DR   Orphanet; 293888; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form.
DR   Orphanet; 293910; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form.
DR   Orphanet; 158687; Lethal acantholytic epidermolysis bullosa.
DR   Orphanet; 34217; Naxos disease.
DR   PharmGKB; PA30009; -.
DR   VEuPathDB; HostDB:ENSG00000173801.16; -.
DR   eggNOG; KOG4203; Eukaryota.
DR   GeneTree; ENSGT00940000156395; -.
DR   HOGENOM; CLU_008757_1_1_1; -.
DR   InParanoid; P14923; -.
DR   OMA; PYPTSDH; -.
DR   OrthoDB; 321213at2759; -.
DR   PhylomeDB; P14923; -.
DR   TreeFam; TF317997; -.
DR   PathwayCommons; P14923; -.
DR   Reactome; R-HSA-418990; Adherens junctions interactions.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-6805567; Keratinization.
DR   Reactome; R-HSA-6809371; Formation of the cornified envelope.
DR   SignaLink; P14923; -.
DR   SIGNOR; P14923; -.
DR   BioGRID-ORCS; 3728; 17 hits in 1001 CRISPR screens.
DR   ChiTaRS; JUP; human.
DR   EvolutionaryTrace; P14923; -.
DR   GeneWiki; Plakoglobin; -.
DR   GenomeRNAi; 3728; -.
DR   Pharos; P14923; Tbio.
DR   PRO; PR:P14923; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P14923; protein.
DR   Bgee; ENSG00000173801; Expressed in esophagus mucosa and 237 other tissues.
DR   ExpressionAtlas; P14923; baseline and differential.
DR   Genevisible; P14923; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IEA:Ensembl.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0016327; C:apicolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0016342; C:catenin complex; IDA:BHF-UCL.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0001533; C:cornified envelope; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IMP:BHF-UCL.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005856; C:cytoskeleton; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; ISS:BHF-UCL.
DR   GO; GO:0030057; C:desmosome; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005916; C:fascia adherens; IEA:Ensembl.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0071665; C:gamma-catenin-TCF7L2 complex; IDA:BHF-UCL.
DR   GO; GO:0014704; C:intercalated disc; IDA:BHF-UCL.
DR   GO; GO:0005882; C:intermediate filament; IEA:Ensembl.
DR   GO; GO:0016328; C:lateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IMP:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:BHF-UCL.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:0030018; C:Z disc; IEA:Ensembl.
DR   GO; GO:0005915; C:zonula adherens; ISS:BHF-UCL.
DR   GO; GO:0045294; F:alpha-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0045296; F:cadherin binding; IPI:BHF-UCL.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:BHF-UCL.
DR   GO; GO:0086083; F:cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication; IC:BHF-UCL.
DR   GO; GO:0106006; F:cytoskeletal protein-membrane anchor activity; IDA:BHF-UCL.
DR   GO; GO:0035257; F:nuclear hormone receptor binding; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0005198; F:structural molecule activity; NAS:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:BHF-UCL.
DR   GO; GO:0034332; P:adherens junction organization; TAS:Reactome.
DR   GO; GO:0086073; P:bundle of His cell-Purkinje myocyte adhesion involved in cell communication; IMP:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IMP:BHF-UCL.
DR   GO; GO:0098609; P:cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB.
DR   GO; GO:0070268; P:cornification; TAS:Reactome.
DR   GO; GO:0002159; P:desmosome assembly; IDA:BHF-UCL.
DR   GO; GO:0050982; P:detection of mechanical stimulus; IDA:BHF-UCL.
DR   GO; GO:0071603; P:endothelial cell-cell adhesion; ISS:BHF-UCL.
DR   GO; GO:0031424; P:keratinization; TAS:Reactome.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IGI:BHF-UCL.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IGI:BHF-UCL.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IC:BHF-UCL.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IGI:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; IMP:BHF-UCL.
DR   GO; GO:0098911; P:regulation of ventricular cardiac muscle cell action potential; IMP:BHF-UCL.
DR   Gene3D; 1.25.10.10; -; 1.
DR   IDEAL; IID00298; -.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000225; Armadillo.
DR   InterPro; IPR013284; Beta-catenin.
DR   InterPro; IPR030461; Plakoglobin.
DR   PANTHER; PTHR45976; PTHR45976; 1.
DR   PANTHER; PTHR45976:SF3; PTHR45976:SF3; 1.
DR   Pfam; PF00514; Arm; 3.
DR   PRINTS; PR01869; BCATNINFAMLY.
DR   SMART; SM00185; ARM; 12.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   PROSITE; PS50176; ARM_REPEAT; 9.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cardiomyopathy; Cell adhesion; Cell junction;
KW   Cytoplasm; Cytoskeleton; Direct protein sequencing; Disease variant;
KW   Glycoprotein; Membrane; Palmoplantar keratoderma; Phosphoprotein;
KW   Reference proteome; Repeat.
FT   CHAIN           1..745
FT                   /note="Junction plakoglobin"
FT                   /id="PRO_0000064278"
FT   REPEAT          132..171
FT                   /note="ARM 1"
FT   REPEAT          172..215
FT                   /note="ARM 2"
FT   REPEAT          216..255
FT                   /note="ARM 3"
FT   REPEAT          258..297
FT                   /note="ARM 4"
FT   REPEAT          298..341
FT                   /note="ARM 5"
FT   REPEAT          342..381
FT                   /note="ARM 6"
FT   REPEAT          383..420
FT                   /note="ARM 7"
FT   REPEAT          423..464
FT                   /note="ARM 8"
FT   REPEAT          470..510
FT                   /note="ARM 9"
FT   REPEAT          512..551
FT                   /note="ARM 10"
FT   REPEAT          574..613
FT                   /note="ARM 11"
FT   REPEAT          615..661
FT                   /note="ARM 12"
FT   REGION          132..297
FT                   /note="Interaction with DSC1 and DSG1"
FT   REGION          574..661
FT                   /note="Interaction with DSC1"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:22223895"
FT   MOD_RES         99
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         125
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         182
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         665
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         730
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CARBOHYD        14
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000269|PubMed:12847106"
FT   VARIANT         19
FT                   /note="T -> I (in ARVD12; unknown pathological
FT                   significance; dbSNP:rs570878629)"
FT                   /evidence="ECO:0000269|PubMed:20031617"
FT                   /id="VAR_065698"
FT   VARIANT         39
FT                   /note="S -> SS (in ARVD12; affects the structure and
FT                   distribution of mechanical and electrical cell junctions)"
FT                   /evidence="ECO:0000269|PubMed:17924338"
FT                   /id="VAR_037803"
FT   VARIANT         142
FT                   /note="R -> H (in dbSNP:rs41283425)"
FT                   /evidence="ECO:0000269|PubMed:19863551,
FT                   ECO:0000269|PubMed:20031617"
FT                   /id="VAR_065699"
FT   VARIANT         648
FT                   /note="V -> I (in dbSNP:rs143043662)"
FT                   /evidence="ECO:0000269|PubMed:20031617"
FT                   /id="VAR_065700"
FT   VARIANT         697
FT                   /note="M -> L (in dbSNP:rs1126821)"
FT                   /evidence="ECO:0000269|PubMed:10902626,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:19863551,
FT                   ECO:0000269|PubMed:20031617, ECO:0000269|Ref.4,
FT                   ECO:0000269|Ref.6"
FT                   /id="VAR_037804"
FT   MUTAGEN         14
FT                   /note="T->A: Abolishes glycosylation. Does not affect
FT                   binding to CDH1, DSC1 or DSG1."
FT                   /evidence="ECO:0000269|PubMed:12847106"
FT   MUTAGEN         19
FT                   /note="T->A: Reduces glycosylation."
FT                   /evidence="ECO:0000269|PubMed:12847106"
FT   MUTAGEN         21
FT                   /note="T->A: Does not affect glycosylation."
FT                   /evidence="ECO:0000269|PubMed:12847106"
FT   MUTAGEN         24
FT                   /note="S->A: Does not affect glycosylation."
FT                   /evidence="ECO:0000269|PubMed:12847106"
FT   MUTAGEN         28
FT                   /note="S->A: Does not affect glycosylation."
FT                   /evidence="ECO:0000269|PubMed:12847106"
FT   MUTAGEN         32
FT                   /note="T->A: Does not affect glycosylation."
FT                   /evidence="ECO:0000269|PubMed:12847106"
FT   CONFLICT        91
FT                   /note="P -> S (in Ref. 4; AAO85780)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        264..270
FT                   /note="VRLADGL -> CAGRRA (in Ref. 1; AAA64895)"
FT                   /evidence="ECO:0000305"
FT   HELIX           127..131
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           133..142
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           144..151
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           156..169
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           173..180
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           183..193
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           199..212
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           216..224
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           227..233
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           234..236
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           240..256
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           260..266
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           269..272
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           274..278
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           282..296
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           300..308
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           311..321
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           325..338
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           344..350
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           353..358
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           359..362
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           366..380
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           390..397
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   TURN            398..401
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           405..418
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   TURN            419..421
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           423..429
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   TURN            430..433
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           434..445
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           449..462
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   STRAND          464..466
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           469..477
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   TURN            478..480
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           481..487
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           488..490
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           495..508
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           512..514
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           515..520
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           523..543
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           556..570
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           574..582
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           586..592
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           598..611
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           615..623
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   TURN            624..626
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           627..633
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           639..651
FT                   /evidence="ECO:0007744|PDB:3IFQ"
FT   HELIX           662..667
FT                   /evidence="ECO:0007744|PDB:3IFQ"
SQ   SEQUENCE   745 AA;  81745 MW;  3519A0973748BCF4 CRC64;
     MEVMNLMEQP IKVTEWQQTY TYDSGIHSGA NTCVPSVSSK GIMEEDEACG RQYTLKKTTT
     YTQGVPPSQG DLEYQMSTTA RAKRVREAMC PGVSGEDSSL LLATQVEGQA TNLQRLAEPS
     QLLKSAIVHL INYQDDAELA TRALPELTKL LNDEDPVVVT KAAMIVNQLS KKEASRRALM
     GSPQLVAAVV RTMQNTSDLD TARCTTSILH NLSHHREGLL AIFKSGGIPA LVRMLSSPVE
     SVLFYAITTL HNLLLYQEGA KMAVRLADGL QKMVPLLNKN NPKFLAITTD CLQLLAYGNQ
     ESKLIILANG GPQALVQIMR NYSYEKLLWT TSRVLKVLSV CPSNKPAIVE AGGMQALGKH
     LTSNSPRLVQ NCLWTLRNLS DVATKQEGLE SVLKILVNQL SVDDVNVLTC ATGTLSNLTC
     NNSKNKTLVT QNSGVEALIH AILRAGDKDD ITEPAVCALR HLTSRHPEAE MAQNSVRLNY
     GIPAIVKLLN QPNQWPLVKA TIGLIRNLAL CPANHAPLQE AAVIPRLVQL LVKAHQDAQR
     HVAAGTQQPY TDGVRMEEIV EGCTGALHIL ARDPMNRMEI FRLNTIPLFV QLLYSSVENI
     QRVAAGVLCE LAQDKEAADA IDAEGASAPL MELLHSRNEG TATYAAAVLF RISEDKNPDY
     RKRVSVELTN SLFKHDPAAW EAAQSMIPIN EPYGDDMDAT YRPMYSSDVP LDPLEMHMDM
     DGDYPIDTYS DGLRPPYPTA DHMLA
//
